S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.34
+1.66
+9.95%
DERM · Journey Medical Corporation
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
Journey Medical Corp (DERM)
NASDAQ NMS - GLOBAL MARKET
Pharmaceuticals
$4.79
-0.45
(-8.59%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$4.79
$4.79
$5.25
52-WEEK RANGE
$4.79
$4.31
$9.55
What's happening
- DERM is down 8.59% today, trading at $4.79. — Live quote
- Volume today (11,073) is well below its 3-month average of 229,810. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.01 actual vs. $-0.02 estimated (+56.3%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 2
Buy 7
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (10 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
DERM
-32.30%
vs S&P 500
-45.07%
1-YEAR RETURN
DERM
-27.80%
vs S&P 500
-42.36%
6-MONTH RETURN
DERM
+0.97%
3-MONTH RETURN
DERM
-28.59%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.01
Est. $-0.02
BEAT +56.3%
2026-04-26 (Q1 2026)
$-0.08
Est. $-0.08
MISS -1.1%
2026-01-26 (Q4 2025)
$-0.05
Est. $-0.06
BEAT +21.6%
2025-10-26 (Q3 2025)
$-0.09
Est. $-0.05
MISS -85.6%
Valuation Measures & Ratios
Enterprise Value4$147.2M
Forward P/E516.21
PEG Ratio6—
Price / Sales (TTM1)2.16
Price / Book74.75
EV4 / Revenue2.16
EV4 / EBITDA121.02
Profit Margin-8.95%
Operating Margin-4.41%
Return on Equity (ROE8)-20.23%
Return on Assets (ROA9)-6.60%
Avg Volume (3M)229,810
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $220.3M | $131.0M | $183.0M | $169.5M | $132.8M |
| P/E | -25.46 | -10.55 | -14.55 | -12.45 | -6.55 |
| Price/Sales | 3.28 | 2.12 | 3.03 | 2.94 | 2.39 |
| Price/Book | 6.86 | 4.25 | 7.07 | 8.81 | 6.17 |
| EV/Revenue | 3.28 | 2.09 | 3.03 | 3.02 | 2.46 |
| ROE | -26.94% | -40.26% | -48.55% | -70.77% | -94.08% |
| ROA | -8.80% | -13.56% | -14.76% | -16.78% | -23.85% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short3,055,846
Change from Prior Settlement+4.38%
% of Float—
Days to Cover (Short Ratio)13.91
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 23.3% on the provider's reported measure. Finnhub fundamentals ↗
- Latest SEC filing is Form 10-Q, filed 2026-08-12; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -8.9%. Finnhub fundamentals ↗
- Trailing 52-week price return is -27.8%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on DERM
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $18.5M | $16.0M | $17.6M | $15.0M | $13.1M | $14.6M | $14.9M | $13.0M |
| Operating income | $456.0K | -$1.5M | -$1.5M | -$2.9M | -$3.3M | -$2.9M | -$2.9M | -$10.1M |
| Net income | -$312.0K | -$2.2M | -$2.3M | -$3.8M | -$4.1M | -$2.4M | -$3.4M | -$10.4M |
| EPS (diluted) | $-0.01 | $-0.08 | $-0.09 | $-0.16 | $-0.18 | $-0.12 | $-0.17 | $-0.53 |
| EPS (basic) | $-0.01 | $-0.08 | $-0.09 | $-0.16 | $-0.18 | $-0.12 | $-0.17 | $-0.53 |
| Operating margin | $2 | -$9 | -$9 | -$19 | -$25 | -$20 | -$20 | -$77 |
| Net margin | -$2 | -$14 | -$13 | -$25 | -$31 | -$16 | -$23 | -$80 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $98.4M | $91.5M | $94.6M | $85.2M | $81.2M | $85.0M | $80.2M | $64.0M |
| Total liabilities | $66.2M | $60.7M | $62.7M | $59.3M | $61.9M | $63.4M | $60.2M | $53.1M |
| Stockholders' equity | $32.1M | $30.8M | $31.9M | $25.9M | $19.2M | $21.5M | $20.1M | $10.9M |
| Total current assets | $72.8M | $65.0M | $66.9M | $56.4M | $51.3M | $54.0M | $48.2M | $46.2M |
| Total current liabilities | $45.8M | $37.8M | $37.4M | $39.7M | $40.5M | $40.2M | $35.2M | $33.3M |
| Cash & equivalents | $25.6M | $27.2M | $24.1M | $24.9M | $20.3M | $21.1M | $20.3M | $22.5M |
| Accounts receivable | $36.2M | $25.0M | $29.8M | $18.0M | $15.6M | $18.0M | $10.2M | $10.7M |
| Inventory | $8.2M | $9.3M | $9.6M | $11.8M | $12.9M | $12.5M | $14.4M | $11.8M |
| Intangible assets | $25.5M | $26.5M | $27.6M | $28.7M | $29.7M | $30.8M | $31.9M | $17.8M |
| Other non-current assets | — | — | — | — | — | — | — | $6.0K |
| Accounts payable | $8.0M | $8.2M | $8.9M | $11.6M | $12.8M | $14.4M | $16.1M | $15.3M |
| Accrued liabilities | $31.8M | $26.1M | $27.6M | $21.2M | $22.6M | $23.0M | $17.4M | $16.0M |
| Short-term debt | $5.0M | $2.5M | — | $5.6M | $3.8M | $1.9M | — | — |
| Other current liabilities | $405.0K | $472.0K | $455.0K | $755.0K | $840.0K | $399.0K | $528.0K | $370.0K |
| Long-term debt | $20.5M | $22.9M | $25.3M | $19.5M | $21.4M | $23.1M | $24.9M | $19.8M |
| Retained earnings | -$101.0M | -$100.7M | -$98.5M | -$97.2M | -$94.9M | -$91.1M | -$87.0M | -$88.5M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.7M | $2.9M | -$6.3M | -$2.4M | -$942.0K | -$2.8M | $2.2M | -$1.2M |
| Investing cash flow | — | — | — | — | — | — | -$15.0M | — |
| Financing cash flow | $158.0K | $220.0K | $5.4M | $7.0M | $165.0K | $3.6M | $10.6M | -$294.0K |
| Depreciation & amortization | — | — | — | — | — | — | — | — |
| Share-based compensation | $1.4M | $989.0K | $1.8M | $1.9M | $1.3M | $1.3M | $1.4M | $1.6M |
| Deferred income taxes | — | — | — | — | — | — | — | — |
| Change in accounts receivable | $11.2M | -$4.8M | $11.8M | $2.4M | -$2.8M | $8.0M | -$747.0K | $877.0K |
| Change in inventory | -$1.1M | -$332.0K | -$2.2M | -$1.0M | $356.0K | -$1.9M | $2.6M | $2.1M |
| Change in accounts payable | -$153.0K | -$649.0K | -$2.7M | -$1.2M | -$1.6M | -$1.6M | $711.0K | $735.0K |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $61.9M | $56.1M | $79.2M | $73.7M | $63.1M |
| Operating income | -$8.2M | -$13.7M | -$2.1M | -$27.5M | -$34.9M |
| Net income | -$11.4M | -$14.7M | -$3.9M | -$29.6M | -$44.0M |
| EPS (diluted) | $-0.47 | $-0.72 | $-0.21 | $-1.69 | $-4.32 |
| EPS (basic) | $-0.47 | $-0.72 | $-0.21 | $-1.69 | $-4.32 |
| Operating margin | -$13 | -$24 | -$3 | -$37 | -$55 |
| Net margin | -$18 | -$26 | -$5 | -$40 | -$70 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $94.6M | $80.2M | $76.8M | $105.2M | $97.3M |
| Total liabilities | $62.7M | $60.2M | $56.5M | $88.2M | $55.2M |
| Stockholders' equity | $31.9M | $20.1M | $20.4M | $17.0M | $42.0M |
| Total current assets | $66.9M | $48.2M | $56.5M | $77.7M | $84.5M |
| Total current liabilities | $37.4M | $35.2M | $41.9M | $66.8M | $51.6M |
| Cash & equivalents | $24.1M | $20.3M | $27.4M | $32.0M | $49.1M |
| Accounts receivable | $29.8M | $10.2M | $15.2M | $28.2M | $23.1M |
| Inventory | $9.6M | $14.4M | $10.2M | $14.2M | $9.9M |
| Intangible assets | $27.6M | $31.9M | $20.3M | $27.2M | $12.6M |
| Other non-current assets | — | — | $6.0K | $95.0K | $150.0K |
| Accounts payable | $8.9M | $16.1M | $18.1M | $36.6M | $22.8M |
| Accrued liabilities | $27.6M | $17.4M | $20.4M | $19.4M | $22.7M |
| Other current liabilities | $455.0K | $528.0K | $195.0K | $413.0K | — |
| Long-term debt | $25.3M | $24.9M | $14.6M | $19.8M | — |
| Retained earnings | -$98.5M | -$87.0M | -$72.4M | -$68.5M | -$38.9M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$12.4M | -$9.1M | $5.2M | -$13.5M | -$2.2M |
| Investing cash flow | — | -$15.0M | -$5.0M | -$20.0M | -$10.0M |
| Financing cash flow | $16.2M | $17.0M | -$4.8M | $16.5M | $53.0M |
| Depreciation & amortization | — | — | — | — | $0 |
| Share-based compensation | $6.3M | $6.1M | $2.6M | $4.4M | $2.5M |
| Deferred income taxes | — | — | — | — | $1.6M |
| Change in accounts receivable | $19.3M | -$4.5M | -$12.6M | $5.4M | -$768.0K |
| Change in inventory | -$4.8M | $4.2M | -$4.0M | -$1.7M | $8.5M |
| Change in accounts payable | -$7.2M | -$2.1M | -$18.4M | $14.3M | $20.4M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding DERM as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-06-17 to 2026-07-01
Recent transactions
- Most recent: Toledano Miranda Jayne (Director) — Grant / award of 50,000 shares on 2026-07-01.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Toledano Miranda Jayne | Director | Grant / award | 2026-07-01 | 50,000 |
| Smith Justin Adam | Director | Grant / award | 2026-07-01 | 50,000 |
| Herskowitz Neil | Director | Grant / award | 2026-07-01 | 50,000 |
| Pearce Michael Cooper | Director | Grant / award | 2026-06-25 | 10,000 |
| ROSENWALD LINDSAY A MD | Director | Grant / award | 2026-06-25 | 10,000 |
| Alloush Ramsey | Chief Operating Officer | Grant / award | 2026-04-22 | 46,863 |
| Benesch Joseph | CFO | Grant / award | 2026-04-22 | 28,907 |
| Maraoui Claude | President & CEO | Grant / award | 2026-04-22 | 49,277 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-07-01 | Toledano Miranda Jayne | Director | Grant / award | 50,000 | $0.00 |
| 2026-07-01 | Smith Justin Adam | Director | Grant / award | 50,000 | $0.00 |
| 2026-07-01 | Herskowitz Neil | Director | Grant / award | 50,000 | $0.00 |
| 2026-06-25 | Toledano Miranda Jayne | Director | Grant / award | 10,000 | $0.00 |
| 2026-06-25 | Smith Justin Adam | Director | Grant / award | 10,000 | $0.00 |
| 2026-06-25 | Herskowitz Neil | Director | Grant / award | 10,000 | $0.00 |
| 2026-06-25 | Pearce Michael Cooper | Director | Grant / award | 10,000 | $0.00 |
| 2026-06-25 | ROSENWALD LINDSAY A MD | Director | Grant / award | 10,000 | $0.00 |
| 2026-04-22 | Alloush Ramsey | Chief Operating Officer | Grant / award | 46,863 | $0.00 |
| 2026-04-22 | Benesch Joseph | CFO | Grant / award | 28,907 | $0.00 |
| 2026-04-22 | Maraoui Claude | President & CEO | Grant / award | 49,277 | $0.00 |
| 2025-08-25 | Maraoui Claude | President & CEO | Option exercise | 1,250,000 | $0.07 |
| 2025-08-25 | Maraoui Claude | President & CEO | Tax withholding | 10,877 | $7.47 |
| 2025-08-05 | ROSENWALD LINDSAY A MD | Director | Grant / award | 50,000 | $0.00 |
| 2025-08-05 | Smith Justin Adam | Director | Grant / award | 20,000 | $0.00 |
| 2025-08-05 | Toledano Miranda Jayne | Director | Grant / award | 20,000 | $0.00 |
| 2025-08-05 | Pearce Michael Cooper | Director | Grant / award | 20,000 | $0.00 |
| 2025-08-05 | Herskowitz Neil | Director | Grant / award | 20,000 | $0.00 |
| 2025-06-25 | Toledano Miranda Jayne | Director | Grant / award | 7,173 | $0.00 |
| 2025-06-25 | ROSENWALD LINDSAY A MD | Director | Grant / award | 7,173 | $0.00 |
| 2025-06-25 | Pearce Michael Cooper | Director | Grant / award | 7,173 | $0.00 |
| 2025-06-25 | Smith Justin Adam | Director | Grant / award | 7,173 | $0.00 |
| 2025-06-25 | Herskowitz Neil | Director | Grant / award | 7,173 | $0.00 |
| 2025-06-17 | Alloush Ramsey | Chief Operating Officer | Grant / award | 46,863 | $0.00 |
| 2025-06-17 | Benesch Joseph | CFO | Grant / award | 28,907 | $0.00 |
| 2025-06-17 | Maraoui Claude | President & CEO | Grant / award | 49,277 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 06:30 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-12 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-12 | 8-K | 2026-08-12 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-07-01 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-07-01 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-07-01 | View on SEC.gov → |
| 2026-06-29 | 4 | 2026-06-25 | View on SEC.gov → |
| 2026-06-26 | 4 | 2026-06-25 | View on SEC.gov → |
| 2026-06-26 | 4 | 2026-06-25 | View on SEC.gov → |
| 2026-06-26 | 4 | 2026-06-25 | View on SEC.gov → |
| 2026-06-26 | 4 | 2026-06-25 | View on SEC.gov → |
| 2026-06-26 | 8-K | 2026-06-24 | View on SEC.gov → |
| 2026-05-13 | 10-Q | 2026-03-31 | View on SEC.gov → |
Recent news
Headlines about DERM (Journey Medical Corporation). Links open the publisher — we don’t host full articles.
-
From its first 15 products to MaruDerm's journey to the global market.
Vietnam.vn · 2026-10-21 -
Celebrity Dermatologist Dr. Sheila Farhang Launches DOSE (OF) DERM, Introducing Clinical Color Cosmetics™, a New Category in Beauty
Yahoo Finance · 2026-10-20 -
Kim Kardashian and Meghan Markle Use the Brand Behind This Derm-Approved Serum That Boosts Hair Growth
شبكة تواصل الإخبارية · 2026-10-20 -
The Biggest Skin Care Myth a Dermatologist Says to Skip—and the Drugstore Finds to Use Instead
Real Simple · 2026-10-19 -
Thinning Hair? Peptides Could Be What You Need — Dermatologists Explain Why
TODAY.com · 2026-10-19 -
DERM Q2 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates, Yet Shares Slip 3.12% - Earnings Growth Forecast
https://www.dars.gov.et/ · 2026-10-19 -
SPF Stacking Is the Derm-Approved Dewy-Makeup Hack I'm Taking Into Fall
Who What Wear · 2026-10-18 -
Why (DERM) Price Action Is Critical for Tactical Trading
Stock Traders Daily · 2026-10-17
No headlines in this category right now — try “All”.